Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track GRML with free AI briefings, catalyst countdowns, and dilution alerts.

GRML · Greenland Mines Ltd

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$57.4M Cash on Hand
20mo Cash Runway
19.9% Short Interest
$110 Analyst Target (1)
Follow GRML by email Get an email when GRML reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about GRML, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

GRML holds $57.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $8.6M/quarter from operations, an estimated runway of 20 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 23 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GRML files for a raise →

👥 Who Owns GRML

Insiders 71% Other 5%+ holders 29% Institutions (40 holders) 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
Strategic EP, LLC 5%+ holder (13G) 6,687,472 45.13% 2026-03-04
Joseph Sinkule
Chief Executive Officer, Director
Insider 6,346,700 42.83% 2026-03-04
AnorTech Inc. 5%+ holder (13G) 1,451,268 9.79% 2026-11-06
CHARDAN CAPITAL MARKETS LLC
10% owner
Insider 1,284,364 8.67% 2024-06-28
Samuel M Zentman
Director · +60,000 options
Insider 1,086,440 7.33% 2026-03-04
Shalom Hirschman
Director
Insider 908,873 6.13% 2026-03-04
Jon McGarity
Director · +60,000 options
Insider 551,277 3.72% 2026-07-20
Davidson Kempner Capital Management LP 5%+ holder (13G) 400,410 2.70% 2026-08-26
Jason David Sawyer
Director
Insider 240,000 1.62% 2026-07-22
Jeff LeBlanc
Chief Financial Officer
Insider 110,406 0.75% 2026-08-25
Private Advisor Group, LLC Institution (13F) 94,875 0.64% 2026-09-30
UBS Group AG Institution (13F) 67,853 0.46% 2026-09-30

Share count 14,819,209 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-10-01
filed 2026-10-05
El-Dada Riad Hussein
Sale (S) 3,500 $9.35 0
2026-08-25
filed 2026-08-25
LeBlanc Jeff
Purchase (P) 14,000 $9.72 110,406
2026-07-22
filed 2026-07-23
Sawyer Jason David
Purchase (P) 240,000 $0.23 240,000
2026-07-20
filed 2026-07-20
McGarity Jon
Purchase (P) 140,000 $0.18 551,277
2026-07-16
filed 2026-07-17
LeBlanc Jeff
Purchase (P) 1,400,000 $0.18 4,820,342

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full GRML picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GRML and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.